Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies

{ 'indexed': {'date-parts': [[2024, 10, 3]], 'date-time': '2024-10-03T04:16:20Z', 'timestamp': 1727928980964}, 'reference-count': 19, 'publisher': 'Case Western Reserve University', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 9, 30]], 'date-time': '2024-09-30T00:00:00Z', 'timestamp': 1727654400000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for ' 'prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because ' 'of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and ' 'AZD3152/Sipavibart, were approved by health authorities, but their activity against ' 'contemporary JN.1 sublineages is poorly characterized.\xa0\n' 'Methods: We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their ' 'sensitivity to neutralization by these mAbs in 2 target cell lines.\xa0\n' 'Results: Compared to ancestral strains, VYD222/Pemivibart remained moderately active against ' 'JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up ' 'to 3 to 15 µg/mL for KP.3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral ' 'efficacy against KP.1.1, LB.1, and KP.3.3.\xa0\n' 'Conclusions: Our results highlight the need for a close clinical monitoring of ' 'VYD222/Pemivibart and raise concerns about the clinical efficacy of ' 'AZD3152/Sipavibart.</jats:p>', 'DOI': '10.20411/pai.v10i1.752', 'type': 'journal-article', 'created': {'date-parts': [[2024, 10, 2]], 'date-time': '2024-10-02T18:01:49Z', 'timestamp': 1727892109000}, 'page': '1-11', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies', 'prefix': '10.20411', 'volume': '10', 'author': [ {'given': 'Delphine', 'family': 'Planas', 'sequence': 'first', 'affiliation': []}, {'given': 'Isabelle', 'family': 'Staropoli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cyril', 'family': 'Planchais', 'sequence': 'additional', 'affiliation': []}, {'given': 'Emilie', 'family': 'Yab', 'sequence': 'additional', 'affiliation': []}, {'given': 'Banujaa', 'family': 'Jeyarajah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yannis', 'family': 'Rahou', 'sequence': 'additional', 'affiliation': []}, {'given': 'Matthieu', 'family': 'Prot', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Florence', 'family': 'Guivel-Benhassine', 'sequence': 'additional', 'affiliation': []}, {'given': 'Frederic', 'family': 'Lemoine', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vincent', 'family': 'Enouf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Etienne', 'family': 'Simon-Loriere', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hugo', 'family': 'Mouquet', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marie-Anne', 'family': 'Rameix-Welti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Olivier', 'family': 'Schwartz', 'sequence': 'additional', 'affiliation': []}], 'member': '7530', 'published-online': {'date-parts': [[2024, 9, 30]]}, 'reference': [ { 'key': '6623', 'doi-asserted-by': 'crossref', 'unstructured': '<p>1.&#9;Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, ' 'Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon ' 'L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer ' 'D, Pere H, Lina B, Trouillet-Assant S, Hocqueloux L, Prazuck T, ' 'Simon-Loriere E, Schwartz O. Distinct evolution of SARS-CoV-2 Omicron ' 'XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody ' 'evasion. <em>Nat Commun</em>. 2024;15(1):2254. doi: <a ' 'href="http://dx.doi.org.10.1038/s41467-024-46490-7" ' 'target="_blank"><span>10.1038/s41467-024-46490-7</span></a>. PubMed ' 'PMID: 38480689; PMCID: PMC10938001.</p>', 'DOI': '10.1038/s41467-024-46490-7'}, { 'key': '6624', 'doi-asserted-by': 'crossref', 'unstructured': '<p>2.&#9;Kaku Y, Yo MS, Tolentino JE, Uriu K, Okumura K, Genotype to ' 'Phenotype Japan C, Ito J, Sato K. Virological characteristics of the ' 'SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. <em>Lancet Infect Dis</em>. ' '2024;24(8):e482-e3. doi: <a ' 'href="http://dx.doi.org/10.1016/S1473-3099(24)00415-8"><span>10.1016/S1473-3099(24)00415-8</span></a>. ' 'PubMed PMID: 38945150.</p>', 'DOI': '10.1016/S1473-3099(24)00415-8'}, { 'key': '6625', 'doi-asserted-by': 'crossref', 'unstructured': '<p>3.&#9;Kaku Y, Uriu K, Kosugi Y, Okumura K, Yamasoba D, Uwamino Y, ' 'Kuramochi J, Sadamasu K, Yoshimura K, Asakura H, Nagashima M, Genotype ' 'to Phenotype Japan C, Ito J, Sato K. Virological characteristics of the ' 'SARS-CoV-2 KP.2 variant. <em>Lancet Infect Dis</em>. 2024;24(7):e416. ' 'doi: <a href="http://dx.doi.org/10.1016/S1473-3099(24)00298-6" ' 'target="_blank"><span>10.1016/S1473-3099(24)00298-6</span></a>. PubMed ' 'PMID: 38782005.</p>', 'DOI': '10.1016/S1473-3099(24)00298-6'}, { 'key': '6626', 'doi-asserted-by': 'crossref', 'unstructured': '<p>4.&#9;Focosi D, Franchini M, Casadevall A, Maggi F. An update on the ' 'anti-spike monoclonal antibody pipeline for SARS-CoV-2. <em>Clin ' 'Microbiol Infect</em>. 2024;30(8):999-1006. doi: <a ' 'href="http://dx.doi.org/10.1016/j.cmi.2024.04.012" ' 'target="_blank"><span>10.1016/j.cmi.2024.04.012</span></a>. PubMed PMID: ' '38663655.</p>', 'DOI': '10.1016/j.cmi.2024.04.012'}, { 'key': '6627', 'doi-asserted-by': 'crossref', 'unstructured': '<p>5.&#9;Cai Y, Diallo S, Rosenthal K, Ren K, Flores DJ, Dippel A, ' 'Oganesyan V, van Dyk N, Chen X, Cantu E, Choudhary R, Sulikowski M, ' 'Adissu H, Chawla B, Kar S, Liu C, Dijokaite-Guraliuc A, Mongkolsapaya J, ' 'Rajan S, Loo YM, Beavon R, Webber C, Chang LJ, Thomas S, Clegg L, Zhang ' 'H, Screaton GR, Philbin N, Harre M, Selim A, Martinez-Alier N, Uriel A, ' 'Cohen TS, Perez JL, Esser MT, Blair W, Francica JR. AZD3152 neutralizes ' 'SARS-CoV-2 historical and contemporary variants and is protective in ' 'hamsters and well tolerated in adults. <em>Sci Transl Med</em>. ' '2024;16(753):eado2817. doi: <a ' 'href="http://dx.doi.org/10.1126/scitranslmed.ado2817" ' 'target="_blank"><span>10.1126/scitranslmed.ado2817</span></a>. PubMed ' 'PMID: 38924429.</p>', 'DOI': '10.1126/scitranslmed.ado2817'}, { 'key': '6628', 'unstructured': '<p>6.&#9;AstraZeneca. Sipavibart EMA regulatory submission accepted ' 'under accelerated assessment for COVID-19 prevention. 2024.</p>'}, { 'key': '6629', 'unstructured': '<p>7.&#9;Fact sheet for healthcare providers: Emergency Use ' 'Authorization of Pemgarda (pemivibart). Invivyd; 2024. Accessed March ' '25, 2024. In: Pemgarda, editor.: FDA.gov; 2024.</p>'}, { 'key': '6630', 'doi-asserted-by': 'crossref', 'unstructured': '<p>8.&#9;Cao Y, Jian F, Zhang Z, Yisimayi A, Hao X, Bao L, Yuan F, Yu Y, ' 'Du S, Wang J, Xiao T, Song W, Zhang Y, Liu P, An R, Wang P, Wang Y, Yang ' 'S, Niu X, Zhang Y, Gu Q, Shao F, Hu Y, Yin W, Zheng A, Wang Y, Qin C, ' 'Jin R, Xiao J, Xie XS. Rational identification of potent and broad ' 'sarbecovirus-neutralizing antibody cocktails from SARS convalescents. ' '<em>Cell Rep</em>. 2022;41(12):111845. doi: <a ' 'href="http://dx.doi.org/10.1016/j.celrep.2022.111845" ' 'target="_blank"><span>10.1016/j.celrep.2022.111845</span></a>. PubMed ' 'PMID: 36493787; PMCID: PMC9712074.</p>', 'DOI': '10.1016/j.celrep.2022.111845'}, { 'key': '6631', 'doi-asserted-by': 'crossref', 'unstructured': '<p>9.&#9;Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, Wang P, Wang J, ' 'Liu J, Yu L, Niu X, Wang J, Wang Y, Shao F, Jin R, Wang Y, Cao Y. Fast ' 'evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. ' '<em>Lancet Infect Dis</em>. 2024;24(2):e70-e2. doi: <a ' 'href="http://dx.doi.org/10.1016/S1473-3099(23)00744-2" ' 'target="_blank"><span>10.1016/S1473-3099(23)00744-2</span></a>. PubMed ' 'PMID: 38109919.</p>', 'DOI': '10.1016/S1473-3099(23)00744-2'}, { 'key': '6632', 'unstructured': '<p>10.&#9;Beijing Boren Hospital. Efficacy and Safety of the ' 'Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological ' 'Disorders Who Are Persistently Positive for COVID-19 [Internet]. ' 'ClinicalTrials.gov identifier: NCT123456. Available from: <a ' 'href="https://clinicaltrials.gov/study/NCT05675943" ' 'target="_blank"><span>https://clinicaltrials.gov/study/NCT05675943</span></a>.</p>'}, { 'key': '6633', 'doi-asserted-by': 'crossref', 'unstructured': '<p>11.&#9;Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah MM, ' 'Planchais C, Porrot F, Guivel-Benhassine F, Van der Werf S, Casartelli ' 'N, Mouquet H, Bruel T, Schwartz O. Syncytia formation by ' 'SARS-CoV-2-infected cells. <em>EMBO J</em>. 2020;39(23):e106267. doi: <a ' 'href="http://dx.doi.org/10.15252/embj.2020106267" ' 'target="_blank"><span>10.15252/embj.2020106267</span></a>. PubMed PMID: ' '33051876; PMCID: PMC7646020.</p>', 'DOI': '10.15252/embj.2020106267'}, { 'key': '6634', 'doi-asserted-by': 'crossref', 'unstructured': '<p>12.&#9;Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais ' 'C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Pere H, ' 'Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen ' 'S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Marti-Carreras J, ' 'Cuypers L, Seve A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, ' 'Bruel T, Mouquet H, Andre E, Schwartz O. Considerable escape of ' 'SARS-CoV-2 Omicron to antibody neutralization. <em>Nature</em>. ' '2022;602(7898):671-5. doi: <a ' 'href="http://dx.doi.org/10.1038/s41586-021-04389-z" ' 'target="_blank"><span>10.1038/s41586-021-04389-z</span></a>. PubMed ' 'PMID: 35016199.</p>', 'DOI': '10.1038/s41586-021-04389-z'}, { 'key': '6635', 'doi-asserted-by': 'crossref', 'unstructured': '<p>13.&#9;Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli ' 'I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, ' 'Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon ' 'E, Schortgen F, Yahyaoui L, Gonzalez M, De Seze J, Pere H, Veyer D, Seve ' 'A, Simon-Loriere E, Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, ' 'van der Werf S, Prazuck T, Schwartz O. Sensitivity of infectious ' 'SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. ' '<em>Nat Med</em>. 2021;27(5):917-24. doi: <a ' 'href="http://dx.doi.org/10.1038/s41591-021-01318-5" ' 'target="_blank"><span>10.1038/s41591-021-01318-5</span></a>. PubMed ' 'PMID: 33772244.</p>', 'DOI': '10.1038/s41591-021-01318-5'}, { 'key': '6636', 'doi-asserted-by': 'crossref', 'unstructured': '<p>14.&#9;Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, ' 'Guivel-Benhassine F, Porrot F, Bolland WH, Nguyen Y, Casadevall M, ' 'Charre C, Pere H, Veyer D, Prot M, Baidaliuk A, Cuypers L, Planchais C, ' 'Mouquet H, Baele G, Mouthon L, Hocqueloux L, Simon-Loriere E, Andre E, ' 'Terrier B, Prazuck T, Schwartz O. Serum neutralization of SARS-CoV-2 ' 'Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal ' 'antibodies. <em>Nat Med</em>. 2022;28(6):1297-302. doi: <a ' 'href="http://dx.doi.org/10.1038/s41591-022-01792-5" ' 'target="_blank"><span>10.1038/s41591-022-01792-5</span></a>. PubMed ' 'PMID: 35322239; PMCID: 35322239.</p>', 'DOI': '10.1038/s41591-022-01792-5'}, { 'key': '6637', 'doi-asserted-by': 'crossref', 'unstructured': '<p>15.&#9;Planchais C, Fernandez I, Bruel T, de Melo GD, Prot M, Beretta ' 'M, Guardado-Calvo P, Dufloo J, Molinos-Albert LM, Backovic M, ' 'Chiaravalli J, Giraud E, Vesin B, Conquet L, Grzelak L, Planas D, ' 'Staropoli I, Guivel-Benhassine F, Hieu T, Boulle M, Cervantes-Gonzalez ' 'M, Ungeheuer MN, Charneau P, van der Werf S, Agou F, French CCSG, Group ' 'CS, Dimitrov JD, Simon-Loriere E, Bourhy H, Montagutelli X, Rey FA, ' 'Schwartz O, Mouquet H. Potent human broadly SARS-CoV-2-neutralizing IgA ' 'and IgG antibodies effective against Omicron BA.1 and BA.2. <em>J Exp ' 'Med</em>. 2022;219(7). doi: <a ' 'href="http://dx.doi.org/10.1084/jem.20220638" ' 'target="_blank"><span>10.1084/jem.20220638</span></a>. PubMed PMID: ' '35704748; PMCID: PMC9206116.</p>', 'DOI': '10.1084/jem.20220638'}, { 'key': '6638', 'doi-asserted-by': 'crossref', 'unstructured': '<p>16.&#9;Elbe S, Buckland-Merrett G. Data, disease and diplomacy: ' 'GISAID’s innovative contribution to global health. <em>Glob Chall</em>. ' '2017;1(1):33-46. doi: <a href="http://dx.doi.org/10.1002/gch2.1018" ' 'target="_blank"><span>10.1002/gch2.1018</span></a>. PubMed PMID: ' '31565258; PMCID: PMC6607375.</p>', 'DOI': '10.1002/gch2.1018'}, { 'key': '6639', 'unstructured': '<p>17.&#9;Shu Y, McCauley J. GISAID: Global initiative on sharing all ' 'influenza data - from vision to reality. <em>Euro Surveill</em>. ' '2017;22(13):30494. doi: <a ' 'href="http://dx.doi.org/10.2807/1560-7917.ES.2017.22.13.30494101" ' 'target="_blank"><span>10.2807/1560-7917.ES.2017.22.13.30494</span></a>. ' 'PubMed PMID: 28382917; PMCID: PMC5388101.</p>'}, { 'key': '6640', 'doi-asserted-by': 'crossref', 'unstructured': '<p>18.&#9;Tsueng G, Mullen JL, Alkuzweny M, Cano M, Rush B, Haag E, Lin ' 'J, Welzel DJ, Zhou X, Qian Z, Latif AA, Hufbauer E, Zeller M, Andersen ' 'KG, Wu C, Su AI, Gangavarapu K, Hughes LD. Outbreak.info Research ' 'Library: a standardized, searchable platform to discover and explore ' 'COVID-19 resources. <em>Nat Methods</em>. 2023;20(4):536-40. doi: <a ' 'href="http://dx.doi.org/10.1038/s41592-023-01770-w" ' 'target="_blank"><span>10.1038/s41592-023-01770-w</span></a>. PubMed ' 'PMID: 36823331; PMCID: PMC10393269.</p>', 'DOI': '10.1038/s41592-023-01770-w'}, { 'key': '6641', 'unstructured': '<p>19.&#9;Wang Q, Guo Y, Ho J, Ho DD. Pemivibart is less active against ' 'recent SARS-CoV-2 JN.1 sublineages. <em>bioRxiv</em>. ' '2024:2024.08.12.607496. doi: <a ' 'href="http://dx.doi.org/10.1101/2024.08.12.607496" ' 'target="_blank"><span>10.1101/2024.08.12.607496</span></a>.</p>'}], 'container-title': 'Pathogens and Immunity', 'original-title': [], 'link': [ { 'URL': 'https://www.paijournal.com/index.php/paijournal/article/download/752/833', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.paijournal.com/index.php/paijournal/article/download/752/830', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.paijournal.com/index.php/paijournal/article/download/752/830', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 10, 2]], 'date-time': '2024-10-02T18:02:01Z', 'timestamp': 1727892121000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.paijournal.com/index.php/paijournal/article/view/752'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 9, 30]]}, 'references-count': 19, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 9, 30]]}}, 'URL': 'http://dx.doi.org/10.20411/pai.v10i1.752', 'relation': {}, 'ISSN': ['2469-2964'], 'subject': [], 'container-title-short': 'PAI', 'published': {'date-parts': [[2024, 9, 30]]}}